Humacyte (HUMA) to Release Earnings on Wednesday

Humacyte (NASDAQ:HUMA) is anticipated to issue its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $0.9230 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:00 AM ET.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The company had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.94 million. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Stock Up 1.5%

HUMA opened at $1.33 on Monday. The business’s fifty day moving average is $1.65 and its two-hundred day moving average is $1.95. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.93 and a current ratio of 2.45. The company has a market cap of $210.63 million, a price-to-earnings ratio of -2.96 and a beta of 1.88. Humacyte has a one year low of $1.15 and a one year high of $6.77.

Insider Buying and Selling

In other Humacyte news, Director Brady W. Dougan sold 591,685 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Laura E. Niklason sold 591,685 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total value of $934,862.30. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 4,482,090 shares of company stock worth $7,466,382. 5.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Humacyte

Several large investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. acquired a new stake in Humacyte in the 2nd quarter worth about $28,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Humacyte by 41.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock worth $96,000 after acquiring an additional 13,407 shares during the period. Financial Advisors Network Inc. purchased a new position in shares of Humacyte during the 2nd quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Humacyte by 25.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,975 shares of the company’s stock worth $161,000 after acquiring an additional 15,649 shares during the last quarter. Finally, Cerity Partners LLC purchased a new stake in Humacyte in the second quarter valued at approximately $35,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on HUMA. UBS Group set a $6.00 price objective on shares of Humacyte in a research report on Monday, October 13th. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Monday, October 6th. HC Wainwright reduced their price target on shares of Humacyte from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, August 17th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.